XML 49 R21.htm IDEA: XBRL DOCUMENT
v3.2.0.727

Collaborative Research and Development Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2015
Astra Zeneca |
Summary of Revenue Recognized under Various Agreements | The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):
| Three Months Ended |  |  | Six Months Ended |
| June 30, |  |  | June 30, |
| 2015 |  |  | 2014 |  |  | 2015 |  |  | 2014 |
Initial payment | $ | 63 |  |  | $ | 180 |  |  | $ | 126 |  |  | $ | 360 |
Subsequent payment |  | 237 |  |  |  | 675 |  |  |  | 474 |  |  |  | 1,350 |
Performance of research activities |  | 630 |  |  |  | 545 |  |  |  | 801 |  |  |  | 1,432 |
Total | $ | 930 |  |  | $ | 1,400 |  |  | $ | 1,401 |  |  | $ | 3,142 |
National Institutes of Health |
Summary of Revenue Recognized under Various Agreements | The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):
| Three Months Ended |  |  | Six Months Ended |
| June 30, |  |  | June 30, |
| 2015 |  |  | 2014 |  |  | 2015 |  |  | 2014 |
NIAID contracts | $ | - |  |  | $ | 965 |  |  | $ | - |  |  | $ | 1,839 |
All other NIH contracts |  | 101 |  |  |  | 42 |  |  |  | 249 |  |  |  | 293 |
Total grant revenue | $ | 101 |  |  | $ | 1,007 |  |  | $ | 249 |  |  | $ | 2,132 |

X
- Definition Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51671369&loc=d3e50766-111635 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51671369&loc=SL6750900-111635 + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |